Search

Your search keyword '"Iwasaki, Akiko"' showing total 459 results

Search Constraints

Start Over You searched for: Author "Iwasaki, Akiko" Remove constraint Author: "Iwasaki, Akiko" Database Unpaywall Remove constraint Database: Unpaywall
459 results on '"Iwasaki, Akiko"'

Search Results

3. Supplementary Data S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)

4. Supplementary Table S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)

5. Supplementary Figure S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)

6. Supplementary Data S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)

7. Supplementary Figure S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)

8. Data from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)

9. Supplementary Table S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)

10. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)

11. Long COVID Characteristics and Experience: A Descriptive Study from the Yale LISTEN Research Cohort

12. Sex differences in symptomatology and immune profiles of Long COVID

13. Compartmentalized ocular lymphatic system mediates eye–brain immunity

14. Post-Vaccination Syndrome: A Descriptive Analysis of Reported Symptoms and Patient Experiences After Covid-19 Immunization

15. Table S7 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

16. Table S2 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

17. Fig S4 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

18. Fig S7 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

19. Fig S4 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

20. Data from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

21. Table S3 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

22. Table S10 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

23. Figure S1 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

24. FIGURE 1 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

25. Fig S6 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

26. Fig S5 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

27. Table S3 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

28. Table S4 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

29. Table S6 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

30. Figure S2 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

31. Table S2 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

32. Supplementary Methods from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

33. Figure S2 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

34. Table S1 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

35. Table S9 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

36. Figure S1 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

37. Fig S9 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

38. FIGURE 2 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

39. Supplementary Methods from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

40. Fig S7 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

41. Fig S10 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

42. Fig S3 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

43. Table S7 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

44. Fig S11 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

45. Fig S9 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

46. Fig S6 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

47. Table S5 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

48. FIGURE 3 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

49. Fig S8 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

50. Fig S5 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans

Catalog

Books, media, physical & digital resources